NYXH - Gunggunge utang jangka dawa Nyxoah SA

This chart of the long-term liability value for Nyxoah S.A. (NYXH) is recorded at 0.04. Nyxoah S.A. (NYXH) develops Genio neurostimulators, where massive trial expenditures are followed by low-cost mass production of chips. High patent barriers and FDA certification protect the business from competitors. The innovative micro-implant, which targets the tongue nerves, relieves patients of sleep apnea without the use of bulky equipment.

Long-term debt reflects the aggregate of obligations with maturities exceeding twelve months, determining the issuer's financial stability and debt load. By analyzing the trajectory of the issuer's long-term liabilities, an investor assesses the company's ability to service loans without compromising liquidity. The current value of 0.04 captures the volume of raised capital. For Nyxoah S.A. (NYXH), such loans are critical for financing implant expansion amid a deficit of operating profit.